Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

BACKGROUND: The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK. METHODS: A Mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharaibeh, M, McBride, A, Bootman, J L, Abraham, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402455/
https://www.ncbi.nlm.nih.gov/pubmed/25791875
http://dx.doi.org/10.1038/bjc.2015.65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402455/
https://www.ncbi.nlm.nih.gov/pubmed/25791875
http://dx.doi.org/10.1038/bjc.2015.65

Ejemplares similares